Nyrada Inc Annual General Meeting Presentation
“Our strategy is to advance highly optimised drug candidates towards a key value inflection point , such as an efficacy… Read more
“Our strategy is to advance highly optimised drug candidates towards a key value inflection point , such as an efficacy… Read more
“Looking forward, we expect Phase I studies for both the Cholesterol-Lowering and Brain Injury Programs will commence in the second… Read more
Canary Capital believe 2022 will be the year of rising volatility which we will focus on in an upcoming newsletter…. Read more
Paul Hart was interviewed by Stockhead regarding the Biotech Sector. Please see below the article published November 5th, 2021. MoneyTalks… Read more